TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04414800
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distilled water
Study: NCT04414800
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1μg/kg intranasal fentanyl
Study: NCT03440814
Drug: Placebo for DCCR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral administration
Study: NCT04539639
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the morning: 2 tablet of 50mg placebo, 1 tablet of 75mg placebo;In the evening: 2 tablet of 50mg placebo, 1 tablet of 75mg placebo.
Study: NCT04084197
Drug: HIP1402
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (HanmiTams Capsule) 0.4mg
Study: NCT04084197
Drug: HIP1801
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4mg
Study: NCT01437397
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled dose-matched placebo, twice per day
Study: NCT01616407
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules identical to MDMA or methylphenidate but containing no active drug
Study: NCT00878423
Drug: AT13387
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two dosing schedules will be evaluated; twice or once weekly dosing, on three weeks out of four. The starting dose for the once weekly schedule was 10mg/m2/dose, given as one hour intravenous (IV) infusions on Days 1, 4, 8, 11, 15 and 18 of a twenty-eight day cycle. The starting dose for the twice weekly schedule, given as one hour intravenous (IV) infusions on Days 1, 8 and 15 of a twenty-eight day cycle, will be 150mg/m2/dose
Study: NCT00878423
Drug: AT13387
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion over one hour on days 1, 4, 8, 11, 15 and 18, every four weeks or intravenous infusion over one hour on days 1, 8 and 15, every four weeks . Treatment may be continued indefinitively in the presence of clinical benefit
Study: NCT00325728
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon placebo matching tablets, orally, once nightly for up to 8 weeks.
Study: NCT01505569
Drug: Anti-seizure prophylaxis
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm E: Lorazepam OR Levetaracetam~* Lorazepam should be given 0.02-0.05 mg/kg/dose, given 30 minutes prior to each busulfan dose and then continuing every 6 hours, maximum dose: 2 mg.~* Levetiracetam should be given 10 mg/kg/dose PO, administered BID, staring 12 hours prior to busulfan, maximum single dose: 1000mg.
Study: NCT01966133
Drug: Ethiodized Oil + Doxorubicin
Normalized name: ethiodized oil
DrugBank: Ethiodized oil (DB00965)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE using doxorubicin-lipiodol mixture
Study: NCT03532035
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the SoC in each cohort will be managed per local institutional guidelines and investigator judgement. SoC treatment options may include, but are not limited to, taking a watch and-wait approach, with or without decreased immunosuppression (i.e., no active treatment), or treatment with IV CDV, ganciclovir, or ribavirin.
Study: NCT01534663
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a prospective, randomized double-blind, placebo-controlled study design. 38 subjects will be randomized to two groups (19 patients in each group), one taking active fish oil and glutamine supplementation and the other taking placebo for 90 days.
Study: NCT01818024
Drug: Matching placebo single dose IV infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo solution available for IV administration.
Study: NCT01818024
Drug: Matching placebo single dose IH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo nebulised solution available for IH administration.
Study: NCT01818024
Drug: Matching placebo repeat dose IV infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo solution available for IV administration.
Study: NCT01818024
Drug: Matching placebo repeat dose IH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo nebulised solution available for IH administration.
Study: NCT00005870
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00840398
Drug: BUSPAR® 30 mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 30 mg, single-dose fed
Study: NCT01515592
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
Study: NCT00377260
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same base formulation of the licensed product Augmentin ES-600™, with the same strawberry cream flavor.
Study: NCT03217175
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given instead of glucagon according to the algorithm in the insulin-only bionic pancreas
Study: NCT01153347
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral, twice daily for 8 weeks
Study: NCT02131194
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sugar pill manufactured to mimic Lenstatin
Study: NCT00642915
Drug: Lantus, Amaryl
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01632566
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules administered orally
Study: NCT01632566
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01632566
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00385632
Drug: Antiretroviral Regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various antiretroviral therapy combinations already being administered to participants
Study: NCT02463175
Drug: Plasmalyte
Normalized name: PLASMALYTE A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boluses of 5ml/kg of plasmalyte
Study: NCT03154047
Drug: NEOD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: humanized monoclonal antibody
Study: NCT00378547
Drug: paracetamol + placebo + placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparing the analgesic effect of combinations of paracetamol + placebo + placebo
Study: NCT03099187
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules three times in a day.
Study: NCT01317433
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline 100 mg daily per os to start 7 days before Cetuximab for 6 weeks.
Study: NCT00002601
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Course 1 - 150 mg/m2 by continuous intravenous infusion for 96 hours.
Study: NCT04343001
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 80mg
Study: NCT00214370
Drug: Propofol-Fentanyl
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00254462
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo for 8 weeks. Dosed once daily, capsule formulation.
Study: NCT02292030
Drug: HTEA
Normalized name: Hydrocortisone Tetraacetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: usually high thoracic epidural anesthesia
Study: NCT01014689
Drug: Adapalene/ BPO vehicle gel with Lymecycline capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel: Topical to the face, once daily in the evening Capsule: 1 capsule once daily in the morning
Study: NCT03169985
Drug: Rosuvastatin 10 mg plus ezetimibe 10 mg orally once a day
Normalized name: rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After the initial 12 months, randomized intervention will be stopped and then this arm will be received either usual dose rosuvastatin plus ezetimibe or high-dose rosuvastatin during the next 24 months by clinical judgement.
Study: NCT03169985
Drug: Rosuvastatin 20 mg orally once a day
Normalized name: rosuvastatin 20 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After the initial 12 months, randomized intervention will be stopped and then this arm will be received either usual dose rosuvastatin plus ezetimibe or high-dose rosuvastatin during the next 24 months based by clinical judgement.
Study: NCT00462228
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After randomization of the subject, subjects will be titrated up to 20 mg of memantine or placebo per day. Memantine and placebo are provided as 5 mg tablets. Subjects will be started at 5 mg per day. The dose will be increased by 5 mg increments to 10 mg per day (5 mg twice per day), 15 mg per day (5 mg and 10 mg as separate doses) and 20 mg per day (10 mg twice per day). The minimum interval between dose increases will be one week. Subjects will take memantine or placebo for 12 weeks during each part of the crossover study. Subjects are randomized to begin either memantine or placebo in each arm of the study.
Study: NCT01547455
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to Control arm take 80mg placebo 12h before surgery with another 40mg 2h before surgery
Study: NCT00999531
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Placebo, sterile saline
Study: NCT00000421
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01697735
Drug: Atorvastatin or Rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Due to the different clinical prescriptions by different doctors and similar Efficacy in lowering lipids.Usually,Participants receive 20mg Atorvastatin daily or 10mg Rosuvastatin to treat hyperlipidemia.
Study: NCT05238402
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin on COVID 19 patienst
Study: NCT00777608
Drug: Comparator: Placebo 5mg (run in)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to donepezil - 5 mg capsules orally for 14 day run in prior to randomization.
Study: NCT00777608
Drug: Comparator: Placebo 5-10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to donepezil, 1 capsule (5 mg) orally, once daily for 14 days.~Matching placebo to donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84).
Study: NCT01383486
Drug: Naproxen sodium ER (BAYH6689)
Normalized name: naproxen Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen Sodium ER (BAYH6689): oral tablet upon incidence of pain
Study: NCT00655590
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebos
Study: NCT01370369
Drug: Testosterone gel (FE 99903)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02297763
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is made of 100mg of corn starch which is melted in 10cc water.
Study: NCT01986491
Drug: JNJ 39393406 30 mg solid Y
Normalized name: Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ 39393406 30 mg solid Y formulation as a hard gelatin capsule orally (by mouth).
Study: NCT01605526
Drug: RO5045337
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple escalating oral doses, Days 1-5 (1-3) of each 28-day cycle, up to 6 cycles
Study: NCT01605526
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2 (75 mg/m2, 50 mg/m2) iv on Day 1 of each 28-day cycle, up to 6 cycles
Study: NCT01986491
Drug: JNJ 39393406 120 mg solid Y
Normalized name: Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ 39393406 120 mg solid Y formulation as a hard gelatin capsule orally (by mouth).
Study: NCT00123734
Drug: ThromboView
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01471886
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Every 8 hours for 4 days.
Study: NCT00960336
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02580279
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03341156
Drug: Frozen Plasma Product, Human
Normalized name: Frozen plasma product, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: If the patient is randomized to receive standard transfusion they will receive 2 U of fresh frozen plasma intravenously before cardiopulmonary bypass and then up to 4-8 U of plasma added to the cardiopulmonary bypass reservoir during rewarming.
Study: NCT01188889
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing schedule of RAD001 for the Phase I portion:~Regimen 1. 5.0 mg q72 hours (400 mg QD); Regimen 2. 5 mg q48 hours (400 mg QD); Regimen 3. 5.0 mg q day (400 mg QD); Regimen 4. 7.5 mg PO q day (400 mg QD.
Study: NCT02574377
Drug: A: myDC vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02574377
Drug: C: combined myDC/pDC vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03620591
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative administration of normal saline
Study: NCT02257658
Drug: Doxycycyline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01202331
Drug: mass treatment with oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For baseline and follow-up surveys prior to azithromycin distribution, a stratified random sample from two age groups will be chosen: 1) 60 study participants younger than 10 years old and 2) 60 study participants aged 10 years and above. Clinical examination will be performed and conjunctival swabs will be taken from all the study participants. Nasopharyngeal swabs will be collected in each community from 15 randomly selected children among the 60 participants under age 10 who were recruited for conjunctival swabbing. Then a single dose of azithromycin will be distributed according to study design: in tablet form for adults; a weight-adjusted tablet dose for children ages 8-10; and pediatric suspension for children ages 1 - 7.
Study: NCT01531920
Drug: placebo + alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B: placebo + alcohol
Study: NCT03574090
Drug: Physiological Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: To demonstrate its efficacy in the prophylaxis of infection to surgical wound will be used in dirty/contaminated emergency surgery and its efficacy will be compared with topical administration of physiological serum alone.
Study: NCT03451773
Drug: M7824
Normalized name: M7824
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,200 or 500mg every 2 weeks by intravenous (IV) infusion
Study: NCT02603120
Drug: ABC/DTG/3TC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600/50/300 mg FDC tablets administered orally once daily without regard to food
Study: NCT02603120
Drug: B/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50/200/25 mg FDC tablets administered orally once daily without regard to food
Study: NCT02603120
Drug: ABC/DTG/3TC Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally once daily without regard to food
Study: NCT02603120
Drug: B/F/TAF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally once daily without regard to food
Study: NCT02469753
Drug: anti-TNF
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01566773
Drug: PT001 Placebo MDI
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00670319
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo one tab orally per day
Study: NCT02294786
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine (Xeloda™) was supplied as a biconvex, oblong, light peach or peach colored film-coated tablet for oral administration. Each light peach colored tablet contained 150mg Capecitabine and each peach colored tablet contained 500mg Capecitabine. Generic versions of capecitabine may have been used within the study if Xeloda cannot be provided. XELODA™ is a trademark of Hoffmann-La Roche AG.
Study: NCT00647686
Drug: Fentanyl Transdermal System 25 mcg/h + Askina Derm Overlay
Approvals — FDA: no, EMA: no, PMDA: no
Description: single application
Study: NCT00647686
Drug: Fentanyl Transdermal System 25 mcg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: single application
Study: NCT00784420
Drug: UK-453,061
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK-453,061 1000 mg once daily for 10 days
Study: NCT01500109
Drug: Oral acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetaminophen administered as a cherry flavored elixir will be dosed preoperatively 15 mg/kg and redosed every 6 hours for 24 hours. Placebo oral acetaminophen will be administered to the other two arms of the study according to the same timetable. Intraoperative opioids (Fentanyl or Morphine) will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
Study: NCT01500109
Drug: Ofirmev®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen is initiated after intravenous access is obtained intraoperatively and before surgical incision. Dosing is age based as follows: 5 months-2 years 12.5 mg/kg, 2-5 years 15 mg/kg. Redosing will be every 6 hours for 24 hours. The two other arms will receive a placebo in the form of normal saline given intravenously. Intraoperative opioids will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
Study: NCT01500109
Drug: Opioid only
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative opioids (Fentanyl or Morphine) will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
Study: NCT00244764
Drug: GW786034
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
Study: NCT00244764
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
Study: NCT02614586
Drug: TAK-058 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-058 placebo-matching, solution.
Study: NCT01849874
Drug: MEK162, MEK inhibitor; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple dose, single schedule
Study: NCT01849874
Drug: Physician's choice chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive one of the following chemotherapies as determined by the physician:~* Liposomal doxorubicin, anthracycline antibiotic; intravenous (multiple dose, single schedule)~* Paclitaxel, mitotic inhibitor; intravenous (multiple dose, single schedule)~* Topotecan, topoisomerase 1 inhibitor; intravenous (multiple dose, single schedule)
Study: NCT03080298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01445561
Drug: Interleukin-2 (100,00 IU/m(2) SQ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100,000 International Units/m2 SQ daily for 5 days
Study: NCT00003437
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003437
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003437
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003437
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03951623
Drug: HMPL-523
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMPL-523 will be oral administrated once daily for 8 weeks and 16 weeks open-label treatment.
Study: NCT03951623
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMPL-523 matching placebo will be oral administrated once daily for 8 weeks and 16 weeks open-label treatment.
Study: NCT01631383
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will arrive the first day (Day 1) for admission and morning l-THP dosing. The l-THP will be dosed as one capsule 30 mg twice daily (matching placebo or l-THP) (total 60 mg daily). Participants will receive 7 total l-THP doses: two doses on Day 1 (morning and evening), two doses on Day 2 (morning and evening), 2 doses on Day 3 (morning and evening) and one dose the morning of Day 4 (cocaine administration day).
Study: NCT00923390
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00977951
Drug: Placebo (vehicle)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 3 and again on day 4
Study: NCT01007773
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl will be initiated and titrated to achieve adequate pain control.
Study: NCT00977951
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 5 and again on day 6
Study: NCT00299104
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral or parenteral repeating dose
Study: NCT00299104
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose